Open AccessP550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE‐3)
Author(s) -
Daver N. G.,
Liu K.,
Werneke S.,
Rustia E.,
Ramsingh G.,
Vyas P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845088.19453.28
Subject(s) - venetoclax , azacitidine , medicine , tolerability , myeloid leukemia , oncology , chemotherapy regimen , placebo , chemotherapy , regimen , myeloid , leukemia , adverse effect , chronic lymphocytic leukemia , pathology , gene expression , dna methylation , gene , biochemistry , chemistry , alternative medicine